Cargando…
Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study
Early treatment with antivirals against SARS-CoV-2 infection can prevent the onset of severe COVID-19 in fragile and immunocompromised patients. In this real-life, prospective, observational study, we evaluated efficacy and safety of a 3-day early treatment with remdesivir in adult and fragile patie...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964994/ https://www.ncbi.nlm.nih.gov/pubmed/36851078 http://dx.doi.org/10.3390/vaccines11020200 |
_version_ | 1784896646910312448 |
---|---|
author | Scotto, Riccardo Buonomo, Antonio Riccardo Iuliano, Antonio Foggia, Maria Sardanelli, Alessia Villari, Riccardo Pinchera, Biagio Gentile, Ivan Federico II COVID-Team, |
author_facet | Scotto, Riccardo Buonomo, Antonio Riccardo Iuliano, Antonio Foggia, Maria Sardanelli, Alessia Villari, Riccardo Pinchera, Biagio Gentile, Ivan Federico II COVID-Team, |
author_sort | Scotto, Riccardo |
collection | PubMed |
description | Early treatment with antivirals against SARS-CoV-2 infection can prevent the onset of severe COVID-19 in fragile and immunocompromised patients. In this real-life, prospective, observational study, we evaluated efficacy and safety of a 3-day early treatment with remdesivir in adult and fragile patients with a diagnosis of SARS-CoV-2 infection who referred to the COVID-19 early treatment service of Infectious Diseases Unit of University of Naples Federico from 10 January 2022 to 31 March 2022. The included patients could be treated with either remdesivir alone or with remdesivir plus a monoclonal antibody with activity against SARS-CoV-2. Among the 62 included patients, we showed low rates of hospitalization (8%), increase in oxygen supplementation (3.2%), ICU admission (1.6%) and death (1.6%). The rate of disease progression was 8% and it was similar in patients treated with remdesivir alone or in combination with monoclonal antibodies (6.7% and 9.4%, respectively; p = 0.531). The rate of adverse drug reaction was low and similar in the two groups (13.3% in patients treated with remdesivir, 15.6% in patients treated with the combination; p = 0.543). Most common adverse events were headache and fever. In conclusion, in our cohort of patients at a high risk of worse COVID-19 outcomes, an early course of remdesivir showed low rates of disease progression and adverse drug reactions. |
format | Online Article Text |
id | pubmed-9964994 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99649942023-02-26 Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study Scotto, Riccardo Buonomo, Antonio Riccardo Iuliano, Antonio Foggia, Maria Sardanelli, Alessia Villari, Riccardo Pinchera, Biagio Gentile, Ivan Federico II COVID-Team, Vaccines (Basel) Article Early treatment with antivirals against SARS-CoV-2 infection can prevent the onset of severe COVID-19 in fragile and immunocompromised patients. In this real-life, prospective, observational study, we evaluated efficacy and safety of a 3-day early treatment with remdesivir in adult and fragile patients with a diagnosis of SARS-CoV-2 infection who referred to the COVID-19 early treatment service of Infectious Diseases Unit of University of Naples Federico from 10 January 2022 to 31 March 2022. The included patients could be treated with either remdesivir alone or with remdesivir plus a monoclonal antibody with activity against SARS-CoV-2. Among the 62 included patients, we showed low rates of hospitalization (8%), increase in oxygen supplementation (3.2%), ICU admission (1.6%) and death (1.6%). The rate of disease progression was 8% and it was similar in patients treated with remdesivir alone or in combination with monoclonal antibodies (6.7% and 9.4%, respectively; p = 0.531). The rate of adverse drug reaction was low and similar in the two groups (13.3% in patients treated with remdesivir, 15.6% in patients treated with the combination; p = 0.543). Most common adverse events were headache and fever. In conclusion, in our cohort of patients at a high risk of worse COVID-19 outcomes, an early course of remdesivir showed low rates of disease progression and adverse drug reactions. MDPI 2023-01-17 /pmc/articles/PMC9964994/ /pubmed/36851078 http://dx.doi.org/10.3390/vaccines11020200 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Scotto, Riccardo Buonomo, Antonio Riccardo Iuliano, Antonio Foggia, Maria Sardanelli, Alessia Villari, Riccardo Pinchera, Biagio Gentile, Ivan Federico II COVID-Team, Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study |
title | Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study |
title_full | Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study |
title_fullStr | Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study |
title_full_unstemmed | Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study |
title_short | Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study |
title_sort | remdesivir alone or in combination with monoclonal antibodies as an early treatment to prevent severe covid-19 in patients with mild/moderate disease at high risk of progression: a single centre, real-life study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964994/ https://www.ncbi.nlm.nih.gov/pubmed/36851078 http://dx.doi.org/10.3390/vaccines11020200 |
work_keys_str_mv | AT scottoriccardo remdesiviraloneorincombinationwithmonoclonalantibodiesasanearlytreatmenttopreventseverecovid19inpatientswithmildmoderatediseaseathighriskofprogressionasinglecentrereallifestudy AT buonomoantonioriccardo remdesiviraloneorincombinationwithmonoclonalantibodiesasanearlytreatmenttopreventseverecovid19inpatientswithmildmoderatediseaseathighriskofprogressionasinglecentrereallifestudy AT iulianoantonio remdesiviraloneorincombinationwithmonoclonalantibodiesasanearlytreatmenttopreventseverecovid19inpatientswithmildmoderatediseaseathighriskofprogressionasinglecentrereallifestudy AT foggiamaria remdesiviraloneorincombinationwithmonoclonalantibodiesasanearlytreatmenttopreventseverecovid19inpatientswithmildmoderatediseaseathighriskofprogressionasinglecentrereallifestudy AT sardanellialessia remdesiviraloneorincombinationwithmonoclonalantibodiesasanearlytreatmenttopreventseverecovid19inpatientswithmildmoderatediseaseathighriskofprogressionasinglecentrereallifestudy AT villaririccardo remdesiviraloneorincombinationwithmonoclonalantibodiesasanearlytreatmenttopreventseverecovid19inpatientswithmildmoderatediseaseathighriskofprogressionasinglecentrereallifestudy AT pincherabiagio remdesiviraloneorincombinationwithmonoclonalantibodiesasanearlytreatmenttopreventseverecovid19inpatientswithmildmoderatediseaseathighriskofprogressionasinglecentrereallifestudy AT gentileivan remdesiviraloneorincombinationwithmonoclonalantibodiesasanearlytreatmenttopreventseverecovid19inpatientswithmildmoderatediseaseathighriskofprogressionasinglecentrereallifestudy AT federicoiicovidteam remdesiviraloneorincombinationwithmonoclonalantibodiesasanearlytreatmenttopreventseverecovid19inpatientswithmildmoderatediseaseathighriskofprogressionasinglecentrereallifestudy |